UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, says it has completed the ...

An IgA anti-transglutaminase 2 (TGA-IgA) antibody cut-off of approximately 6.1 times the upper limit of normal optimised celiac disease diagnosis in children and adolescents with type 1 diabetes ...

Annie Antar, MD, PhD, spoke about how long viral clearance could be an indicator of long COVID, but more research would need to be done to confirm this.

Under normal conditions, "vaccines generate a response through pneumococcus-specific IgG antibodies. However, in patients with IgA deficiency, the lack of IgA reduces the vaccine's effectiveness," ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to ...

PRINCETON, NJ, USA & TOKYO, Japan I March 31, 2025 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd.

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...